Latest news

• EMA launches rolling review of Regeneron’s COVID-19 antibody cocktail

  Study suggests REGN-COV2 can reduce viral load in non-hospitalised patients with COVID-19. ... populations. The first exploratory analysis found that passive vaccination with REGN-COV2 resulted in 100% prevention of symptomatic COVID-19 infections.

• Regeneron’s COVID-19 antibody cocktail scores FDA emergency approval

  On a key clinical endpoint, REGN-COV2 treatment reduced COVID-19-related medical visits by 57% until day 29. ... Treatment with REGN-COV2 also reduced COVID-19-related medical visits by 72% in patients with one or more risk factors.

• Eli Lilly’s COVID-19 antibody scores FDA emergency use approval

  Another drugmaker, Regeneron, is also looking to obtain an EUA from the FDA for its COVID-19 antibody cocktail, REGN-COV2. ... In October, Regeneron published results for REGN-COV2 which showed that the antibody cocktail induced a greater than ten-fold

• Regeneron halts enrolment of severely ill patients in COVID-19 antibody trial

  According to Regeneron, the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail COVID-19 treatment trials recommended that the current hospitalised patient study be modified. ... The US Food and Drug Administration (FDA) is

• Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses

  Under the terms of the deal, Roche and Regeneron will jointly fund and execute the ongoing phase 3 prevention trials of the drug, REGN-COV2, as well as further phase 1